for the TIMI Investigators
and morbidity. The principal objective of the Thrombolysis in Myocardial Infarction Phase II (TIMI II) trial was to determine whether these sequelae would be minimized by routine coronary arteriography and percutaneous transluminal coronary angioplasty See p 695 (PTCA) (when the anatomy is suitable) 18-48 hours after the start of thrombolytic therapy compared with no angiography or PTCA unless the patient developed symptoms or evidence of uncontrolled spontaneous or inducible myocardial ischemia.9 Within this study, the effects of immediate versus deferred ,8-blocker therapy were assessed in patients eligible to be randomized to receive either immediate pB-blocker therapy or deferred p8-blocker therapy.
,3-Blocker therapy was selected for study for several reasons. Selected ,3-blockers administered commencing days or weeks after myocardial infarction to patients at risk for future clinical events have prolonged survival.10"1' Also, ,-blockers given intravenously in the early hours following the onset of acute myocardial infarction have been shown to reduce early mortality.12 ,8-Blockers are used widely for the treatment of angina and hypertension; thus, some patients are already receiving p-blockade at the time they develop their myocardial infarction. However, the role of (3-blockers in patients recovering from myocardial infarction who have received thrombolytic therapy has not yet been assessed, and (8-blockers given with reperfusion therapy to animals following coronary occlusion appear to be beneficial in reducing infarct size and improving cardiac function.1314 On the other hand, since reperfusion is associated with transient impairment of regional contractility,'3 the possibility that ,B-blockade may have a deleterious effect should be determined. Prior to the thrombolytic era, (3-blockers were recommended in patients surviving myocardial infarction, primarily for long-term benefit.5"16 However, following thrombolysis, unlike the recognized, conventional vulnerable period of 6-12 weeks following myocardial infarction, the highly vulnerable period may start earlier-within hours to days of perfusion,8 and thus, the potential for immediate benefit exists. Accordingly, the TIMI 1I-B study was designed to assess prospectively whether ,p-blockers are beneficial if given immediately with the thrombolytic agent as opposed to being delayed for [6] [7] [8] days.
The overall design of the TIMI II trial and the results of invasive versus conservative strategies have been published.9 In this paper, the results of immediate and delayed metoprolol therapy on regional and global left ventricular function, recurrent myocardial ischemia, reinfarction, and mortality are presented.
Methods

Patient Selection
The TIMI II trial compared an invasive strategy (routine angiography and PTCA, where indicated, at 18-48 hours) and a conservative strategy (angiography for possible angioplasty only in the event of recurrent ischemic symptoms or an ischemic response to predischarge submaximal exercise study) in 3,534 patients with acute myocardial infarction treated with recombinant tissue-type plasminogen activator (rt-PA), heparin, and aspirin.9 Patients were .75 years of age and were treated c4 hours after the onset of chest pain. The diagnosis of acute myocardial infarction was based on chest pain suggestive of acute myocardial ischemia lasting .30 minutes and ST segment elevation of 0.1 mV in two electrically contiguous leads. Exclusion criteria included any of the following: history of a cerebrovascular event, blood pressure of .180 mm Hg systolic or > 110 mm Hg diastolic, bleeding disorder, surgery within the previous 2 weeks, recent prolonged cardiopulmonary resuscitation, PTCA or severe trauma within 6 months, previous coronary artery bypass surgery, prosthetic heart valve replacement, left bundle branch block, dilated cardiomyopathy, or other serious illness. In the clinical centers participating in the TIMI 11-B study, patients were evaluated to determine whether they were eligible to be randomized to receive immediate or deferred pB-blocker therapy. Patients were excluded from randomization if they had one or more of the following: an implanted pacemaker; a resting ventricular rate consistently <55 beats/min; a systolic blood pressure consistently <100 mm Hg; moist rales that did not clear with cough extending above the lower one third of the lung fields or pulmonary edema with consistent chest radiographic findings; advanced first-degree or more advanced heart block; asthma by history; wheezing on physical examination, or chronic obstructive lung disease requiring chronic therapy with corticosteroids or 8,2-stimulants; or p-blocker, ve- rapamil, or diltiazem therapy on admission.
Of the 2,948 patients enrolled in the TIMI 1I-B clinical centers, 1,434 (49%) were eligible for the p-blocker study and were randomized to invasive or conservative strategy. The remaining 1,514 patients were excluded because of one or more of the following: p3-blocker, verapamil, or diltiazem therapy on admission (45.4%), resting ventricular rate consistently <55 beats/min (27.1%) hours) catheterization and PTCA, or no catheteriza-tion and PTCA (conservative strategy). The results for TIMI 11-A have been reported.17,18 Administration of Metoprolol All patients received rt-PA intravenously, and eligible patients were assigned to receive either immediate intravenous /3-blocker therapy or delayed oral ,B-blocker therapy, which was started on day 6. In the immediate intravenous group, metoprolol was given as soon as possible after initiating rt-PA. Three intravenous injections of 5 mg metoprolol were given at 2-minute intervals, for a total intravenous dose of 15 mg. Heart rate, rhythm, and systolic blood pressure were monitored, with readings obtained at a minimum of 1-minute intervals during the intravenous administration of the drug and at 1-2- (2.5 mg) if the patient exhibited an increase in heart rate to >49 beats/min or systolic blood pressure to >95 mm Hg within 10 minutes. Patients who did not meet these hemodynamic requirements within 10 minutes but who had heart rates of >45 beats/min and systolic blood pressures of >95 mm Hg 6 hours later were started on oral metoprolol at 25 mg every 12 hours. Fifteen minutes after the administration of the third intravenous dose of metoprolol, patients were given 50 mg orally every 12 hours during the first 24 hours and 100 mg orally every 12 hours thereafter. In patients assigned to the delayed oral /3-blocker group, on day 6 (at least 48-72 hours before the radionuclide ventriculogram), all patients were given 50 mg metoprolol twice daily for 1 day and then 100 mg metoprolol twice a day for as long as they remained within the study and tolerated this agent clinically.
Concomitant Therapy
All patients received rt-PA <4 hours after the onset of symptoms. The total dose of rt-PA used during the first 6 months of recruitment for TIMI II was 150 mg administered intravenously over 6 hours. Because of an unacceptable incidence of intracranial hemorrhage, the dose was subsequently reduced to 100 mg in the remaining patients. 919 The regimen consisted of a 6 mg initial bolus dose followed by 54 mg in the first hour, 20 mg in the second hour, and 5 mg in each of the next 4 hours. Patients received lidocaine in the form of a bolus injection of 1-1.5 mg/kg followed by an infusion of 2-4 mg/min for a minimum of 24 hours. Heparin was initiated at the same time as rt-PA, with a 5,000-unit bolus injection followed by a continuous infusion at the rate of 1,000 units/hr; the dose was adjusted to maintain an activated partial thromboplastin time of 1.5-2 times control values. Aspirin at 80 mg/day was initiated on day 1 in the first 93 patients and on day 2 in the remainder. The aspirin dose was increased to 325 mg/day in all patients on day 6, when intravenous heparin was replaced by subcutaneous heparin (10,000 units twice a day) until hospital discharge.
Radionuclide Angiography
Equilibrium radionuclide angiography was performed prior to hospital discharge and again at 6 weeks. The procedure was performed according to a standardized protocol in all participating centers. 20 The Radionuclide Core Laboratory identified each patient only by code name and number and was unaware of any clinical information. Global left ventricular ejection fraction was estimated from the left anterior oblique projection in the standard fashion (end-diastolic counts-end-diastolic counts-.÷end-systolic counts). Regional left ventricular ejection fraction was estimated, as previously described,20 from the left anterior oblique projection by dividing the left ventricular end-diastolic region of interest into five segments: basal septal, apical septal, inferoapical, inferolateral, and posterolateral. The radionuclide ventriculogram was performed at rest and during exercise in the supine position on a bicycle ergometer to a heart rate of 120 beats/min for a maximum workload of 67 W (400 kg-mimin).
Coronary arteriography was recommended in patients assigned to the conservative strategy who had either recurring ischemia or a positive exercise study, as defined below. The need for subsequent PTCA or coronary artery bypass grafting (CABG) was determined on the basis of specific anatomic findings and clinical considerations in each patient. In the invasive strategy arm, patients underwent contrast ventriculography routinely and global and regional function were analyzed, as previously outlined.21 A maximal supine bicycle exercise test with electrocardiogram and radionuclide ventriculography was performed in all patients at 6 weeks, and the development of angina or the appearance of ST segment depression or a decrease in the ejection fraction of >5% was considered indicative of a positive exercise test.
End Points
The primary end point selected for comparing the effects of immediate and deferred /3-blocker therapy was global left ventricular ejection fraction as measured by resting radionuclide ventriculography performed prior to hospital discharge. The effects of /3-blocker therapy were assessed by pooling the results for the invasive and conservative strategies and for each strategy separately. Power calculations indicated that with a study goal of 340 patients in each of the four treatment groups (two strategies within each of the two /3-blocker groups), the study had a power of at least 80% to detect differences of 3 units in mean resting ejection fraction among the treatment groups.
Thus, there was adequate power even if the effects of immediate 83-blocker therapy were different in the two strategy groups. Prespecified secondary end points included resting left ventricular ejection fraction at 6 weeks, left ventricular ejection fraction on exercise both at hospital discharge and at 6 weeks, and regional left ventricular ejection fraction in the infarcted area at rest and on exercise prior to hospital discharge and at 6 weeks. Patients were also monitored for clinical events including myocardial ischemia. Recurrent chest pain in the hospital refers to chest pain that occurred with or without myocardial infarction as reported to the nurse during the hospital stay. Severe ischemic event in patients after discharge refers to chest pain occurring with or without myocardial infarction for which the patient was admitted to the hospital. Myocardial infarction was diagnosed when the patient had prolonged chest pain with characteristic electrocardiographic changes and/or confirmatory cardiac enzymes. The treatments were also compared in subgroups of patients defined by baseline characteristics. At the time of randomization, patients were categorized according to risk, with not-low-risk patients defined as those having one or more of the following: history of myocardial infarction, ST segment elevation of anterior electrocardiographic leads, rales extending upward to include more than one third of the lung fields, hypotension (systolic blood pressure of < 100 mm Hg) and sinus tachycardia (atrial rate of > 100 beats/min), atrial fibrillation or flutter, age of .70 years, pulmonary edema, or cardiogenic shock. None of these features were present in the low-risk patients. Patients were also classified into two subgroups by the time from the onset of symptoms to the initiation of rt-PA treatment as early-treatment (.2 hours after the onset of symptoms) and not-early-treatment (2-4 hours after the onset of symptoms) patients.
One analysis of the primary end point was based only on the results for patients who had the hospital discharge radionuclide study performed. A second analysis was performed to estimate the effect of data missing because of deaths. In this analysis, patients who died before the predischarge radionuclide study could be obtained were assigned an ejection fraction of 0.
The statistical comparisons of ejection fraction for the defined groups were based on two-sample tests of means. For the primary end point, p<0.05 (for a two-sided test) was considered significant. The two ,p-blocker groups were also compared with respect to other end points based on the radionuclide studies prior to hospital discharge and at 6 weeks and with respect to clinical events. To adjust for multiple testing, p<0.01 (for a two-sided test) was specified for these comparisons.
All patients were included in the group to which they were randomized originally whether or not immediate p-blocker therapy was given and whether or not PTCA was actually performed within the time specified for that treatment group. The results presented in this report are based on all data processed in the TIMI Coordinating Center as of December 1989. All analyses were performed using SAS. 22 The Breslow-Day test for homogeneity of odds ratios was used to evaluate whether the effects of immediate ,-blocker therapy differed in the two strategies or whether immediate p-blocker therapy could be considered as having a common effect in both strategies.
For the major clinical events, Kaplan-Meier life table curves for the immediate and deferred p-blocker groups were compared using the log rank test. 23 The immediate and deferred p-blocker groups were also compared in subgroups of patients defined by baseline characteristics, and the immediate versus deferred }-blocker difference in the incidence of the end point in the first subgroup was also compared with that difference in the second (complementary) subgroup by a test of interaction. The Breslow-Day test for homogeneity of odds ratios was used to evaluate whether the effect of immediate ,-blocker therapy differed in the two subgroups or whether immediate ,-blocker therapy could be considered as having a common effect (with random variability) in both subgroups. Because of multiple tests for these comparisons, p<0.001 is considered to be necessary for the difference to be significant.
Results
Baseline Characteristics
Of the 1,434 patients enrolled in the ,-blocker substudy, 720 were randomized to the immediate 
Effect of Therapy on Clinical Variables
The systolic blood pressure in the immediate /B-blocker group decreased during the first hour on the average by 9.8% compared with 7.1% in the deferred /3-blocker group (p<0.01). The average diastolic blood pressures did not differ significantly between the two groups. The mean heart rate decreased by 6% in the immediate group compared with an increase in the deferred group (p<0.001) throughout the initial 3 hours of rt-PA treatment. The occurrence of accelerated idioventricular rhythm during rt-PA infusion was more common in the immediate group than in the deferred group (36.5% versus 31.1%, p=0.03) . Otherwise, neither the appearance nor the resolution of dysrhythmias differed significantly between the two /3-blocker arms.
Although chest pain was present in 87.4% of the 1,434 patients enrolled in the /3-blocker substudy when rt-PA was initiated and in only 22.0% upon completion of rt-PA infusion, the proportion of patients having diminished chest pain or marked relief of chest pain did not differ between the immediate and deferred /3-blocker groups (Table 2) . Furthermore, there were no differences between groups with respect to the frequency of rapid normalization or exacerbation of ST segment abnormalities.
Hemorrhagic Events
The dose of rt-PA was 100 mg in 87.6% (631) of the 720 patients in the immediate /3-blocker group and in 86.4% (617) of the 714 in the deferred /3-blocker group; in the remaining patients the dose was 150 mg (Table 3) . Hemorrhagic complications were more common with the higher dose of rt-PA, but they occurred with similar frequency in the two ,3-blocker groups with the exception that intracranial hemorrhage was less frequent among patients in the immediate /3-blocker group. Among the patients receiving 150 mg rt-PA, two assigned to immediate /3-blocker therapy sustained intracranial hemorrhage .6 days after entry compared with five in the deferred /3-blocker group (difference not significant). Among patients receiving 100 mg rt-PA, none assigned to immediate /3-blocker therapy sustained intracranial hemorrhage s6 days after entry compared with five in the deferred /3-blocker group, a trend suggestive of a protective effect but not significant by study criteria (p=0.03). There was no difference in the plasma levels of plasminogen, fibrin degradation products, or fibrinogen between patients fl-blocker groups. Furthermore, the baseline exercise ejection fraction, the difference between the peak and baseline exercise ejection fractions, and the infarcted zone ejection fraction did not differ between the p-blocker arms either at hospital discharge or at 6 weeks (Table 5 ).
In the invasive strategy arm, assessment of left ventricular function was also available from contrast ventriculography, with global ejection fraction in the subgroup assigned to immediate fl-blocker therapy averaging 48.2, which was similar to the average of 47.2 in the subgroup randomized to delayed p-blocker therapy. The regional function determined by contrast ventriculography was also similar between the two subgroups, with the infarcted segment of maximal hypokinesis averaging -2.54 in the immediate p-blocker subgroup and -2.63 (p=0.25) in the deferred fl-blocker subgroup.
Secondary End Points
There was no difference between the immediate and deferred fl-blocker groups at 1 year for the secondary end points of death and reinfarction, alone or in combination (Tables 6 and 7 ). Reinfarction was less common at 6 days and 6 weeks in the patients assigned to receive immediate fl-blocker therapy, but there was no difference at 1 year (Tables 6 and 7 ). In the immediate fl-blocker group the incidence of reinfarction increased from 4.5% at 6 weeks to 8.6% at 1 year, which is similar to the incidence of 9.6%
observed at 1 year in the deferred fl-blocker group.
The 91% increase in the incidence of reinfarction from 6 weeks to 1 year (4.5% to 8.6%) in the immediate fl-blocker group is significantly greater than the 32% increase (7.3% to 9.6%) in the deferred fl-blocker group over the same interval. There was also a lower incidence of recurrent chest pain within the first 6 days in the immediate group than in the deferred group. In the low-risk subgroup, there were no deaths at 6 weeks among the patients randomized to immediate l3-blocker therapy in contrast to seven deaths among those assigned to deferred fl-blocker therapy (Table 8 ). However, survival at 6 weeks was similar in the two fl-blocker arms among the patients classified as not-low-risk (Table 13-blocker group (Table 9) . However, this difference was not evident at 1 year (Table 9 ). In patients treated >2 hours after onset, the frequency of mortality and reinfarction were similar regardless of whether they were assigned to the immediate or deferred 13-blocker group.
Exercise Testing
Bicycle exercise tests were performed at hospital discharge in 83.5% (1, 198) and at 6 weeks in 79.9% (1, 146) of the 1,434 study patients. Clinical, electrocardiographic, and radionuclide ventriculographic indexes of myocardial ischemia were present individually and collectively with equal frequencies in the immediate and deferred P-blocker groups.
Discussion
The primary objective of this study was to compare the effect of immediate intravenous versus delayed (mean 2.6) well as mortality, reinfarction, and recurrent ischhours after the onset of symptoms with one half of emic events. The results indicate that global resting the patients receiving fl-blockers c2 hours after the left ventricular ejection fraction prior to hospital initiation of thrombolytic therapy; in the remaining discharge did not differ between the immediate and one half fl-blockers were deferred until days 6-8. deferred pl-blocker groups. Further, the response to The primary end point of the study was the global peak exercise was similar in the two regimens. Reresting left ventricular ejection fraction measured gional function assessed by radionuclide and, in the just prior to hospital discharge, with secondary end invasive strategy arm, by contrast ventriculography points being resting regional ventricular function and showed no difference between the immediate and deferred ,3-blocker groups. Regional ejection fracdays, the functional status of the infarcted region tion, adjusted for the infarct-related artery, did not correlated with long-term survival. Metoprolol given show significant differences either at rest or at peak to patients with a first myocardial infarction immediexercise prior to hospital discharge, and similar reately after acute angioplasty was associated with sults were observed at 6 weeks. These results indicate improved function of the infarcted region measured 9 that although it is safe to administer metoprolol to days after coronary recanalization.25 These studies appropriately selected patients with acute myocardial suggest that any significant improvements in ventricinfarction immediately following thrombolytic therular function would have been detected, and thus our apy, the lack of a benefit on ventricular function by lack of a difference in ventricular function between immediate /3-blocker administration requires further patients assigned to the immediate and delayed discussion.
P-blocker groups suggests that early p-blocker therSheehan et a121 recently demonstrated that the apy is not associated with any important improvefunctional changes in the infarcted zone early after ments in ventricular function. Animal experiments myocardial infarction have important prognostic imsuggest that immediate /3-blockade can augment the plications. Following thrombolytic therapy infarct salvage of infarcting myocardium accomplished by zone function declined in all patients, but it declined coronary reperfusion. In anesthetized dogs, timolol least in those with sustained reperfusion.24 After 3 administered 15 minutes into a 3-hour period of In the TIMI 11-B study, /3-blockade was induced by the administration of metoprolol. Throughout the initial 3 hours of treatment with intravenous metoprolol, the heart rate was approximately 6% lower than that in the group that received /3-blocker after 6 days; during the first hour systolic blood pressure decreased by 9.8% compared with 7.1% in the delayed ,B-blocker group. Metoprolol, however, did not seem to have an impact on left ventricular function. It is conceivable that the lack of a change in the regional and global ejection fractions was related to the timing of the radionuclide ventriculography. Early improvement of the infarcted region by immediate /3-blockade might no longer be detectable in studies performed prior to hospital discharge. However, this is unlikely to be the reason since in the patients assigned to the invasive strategy who underwent cardiac catheterization 18-48 hours after randomization, infarct zone function was similar in the two /3-blocker groups. The lack of improvement in the global ejection fraction might have been related to opposing changes, contractility increasing over time in the infarcted region while decreasing in the noninfarcted zone. 29 On the other hand, it is conceivable that immediate /3-blocker treatment did not change infarct zone function sufficiently to be detected by radionuclide ventriculography since patients with cardiac failure (who would be expected to have severely depressed ejection fractions and the greatest potential for improvement) were excluded from the /3-blocker study. Using the same methodology in the TIMI I and TIMI II studies, however, infarct zone function tended to be better in patients treated with rt-PA than in those treated with streptokinase.20,30 Therefore, we conclude that immediate ,/-blocker therapy is unlikely to have a substantial benefit on ventricular function.
The secondary end point total mortality was also unaffected by the timing of administration of /3-blockade since at 6 weeks mortality was 3.5% in the deferred ,3-blocker group and 3.6% in the immediate ,3-blocker group; at 1 year mortality was 5.0% and 4.8%, respectively. In the low-risk subgroup, the data indicate a reduced mortality among patients randomized to immediate /8-blocker therapy. At 6 weeks, there were no deaths among the patients randomized to immediate /3-blocker therapy compared with seven deaths among those assigned to deferred /3-blocker treatment; this difference was still evident at 1 year but was not significant by study criteria. These results, however, should be interpreted with caution since they represent a subgroup, albeit a prespecified subgroup, of the study patients; because of the small number of patients the results may reflect random chance rather than a therapeutic effect of /3-blockade. Thus, we do not recommend the use of early /3-blockers for prevention of death in this low-risk subgroup. In the other prespecified subgroup (i.e., patients receiving rt-PA treatment <2 hours after the onset of symptoms), the incidence of reinfarction and death was compared between patients assigned to the immediate and deferred /3-blocker groups. The incidence of the combined end points of reinfarction and death was less among patients assigned to immediate /3-blocker therapy, but for only one interval, namely, 6 weeks (5.4% versus 13.7%, p<0.007) . Considering that this is a subgroup analysis of a secondary end point, these data, while suggestive, were not considered sufficient to warrant a recommendation regarding clinical use of /3-blockers for prevention of death or reinfarction even when given c2 hours after the onset of symptoms.
The incidence of reinfarction and recurrent chest pain in the immediate /3-blocker group at 6 days was less than that in the deferred /-blocker group (p=0.02). These results are similar to those reported in previous /8-blocker trials that were not associated with thrombolytic therapy. [10] [11] [12] [31] [32] [33] Thus, it would appear reasonable to recommend early /3-blockade for prevention of ischemia and reinfarction during the first week following thrombolytic therapy. This difference, however, was not maintained between the two groups at 1 year. While these results suggest that the beneficial effect of /3-blockade was transient, we cannot from this study make meaningful observations as to why this occurred.
The suggestion of the ISIS-1 investigators12 that immediate /3-blockade may decrease the incidence of cardiac rupture could not be supported by the TIMI II /B-blocker study. Twelve patients sustained fatal ventricular rupture in the immediate ,3-blocker group, 11 in the not-low-risk subgroup. Four ruptures occurred .48 hours after initiation of treatment, three more during the subsequent hospital phase, and five between hospital discharge and 1 year. In the deferred 13-blocker group, six fatal ventricular ruptures were observed, four in the not-low-risk subgroup. Three ruptures occurred during the initial 2 days of hospitalization and three during the subsequent hospital phase. The diagnosis of cardiac rupture was confirmed by autopsy in six instances. In the remaining patients, the diagnosis was made clinically.
Complications of rt-PA and metoprolol therapy were prospectively considered as secondary end points in the TIMI IL-B study. The results suggest that the distribution of intracranial hemorrhages differed between the two 13-blocker groups. There were two intracranial hemorrhages in the immediate and 10 in the deferred 13-blocker group. In both groups, hemorrhages occurred more frequently among patients receiving 150 mg rather than 100 mg rt-PA. Although these data are of interest, they also need to be interpreted with caution. Because of multiple secondary end points in the TIMI IL-B study, the probability value of 0.02 does not indicate statistical significance. The results could represent a cluster of rare events in a relatively small population. During the pilot phase of the TIMI II study,19 five (1.5%) of 326 patients treated with 150 mg rt-PA developed intracranial hemorrhage. In contrast, intracranial hemorrhage occurred in only two (0.5%) of 386 patients in the TAMI I study34 also treated with 150 mg rt-PA and an adjunctive regimen comparable to that of the TIMI II pilot study. A similar variability was observed in two European cooperative studies. 35, 36 Although patients in each of these studies received 100 mg rt-PA, they were treated by the same centers and physicians using the same inclusion/ exclusion criteria. Only one (0.3%) of 367 patients suffered an intracranial hemorrhage in the study assessing the value of emergency angioplasty35 in comparison with five (1.4%) of 355 treated patients in the placebo-controlled study. 36 Alternatively, metoprolol itself could have a protective effect and prevent intracranial hemorrhage. Regions of the brain with decreased vascular reserve because of atherosclerosis, thrombosis, and emboli are at risk for bleeding by lysis of thrombus, a systemic lytic state, impaired platelet function, and/or sudden changes in cerebral perfusion pressure. 13-Blockade might have an impact on the risk of intracranial hemorrhage by altering some of these potential triggers. During the initial 3 hours of treatment, systolic blood pressure was approximately 10% lower in the immediate than in the deferred 13-blocker group. Immediate 13-blocker therapy did not alter rt-PA kinetics. Plasma rt-PA levels, available in approximately 50% of the patients, did not differ between the two 13-blocker groups. As expected, there were no differences in the plasma levels of fibrinogen and fibrin degradation products in the two 13-blocker groups. In previous studies, it has been shown that metoprolol does not alter ADP-induced platelet aggregation in patients with severe coronary artery disease37 or acute myocardial infarction38 or in normal volunteers.39 In contrast to propranolol, metoprolol did not significantly alter platelet aggregation, platelet cyclic AMP content, and fibrinolytic activity in hypertensive patients. 40 The 1,1-selective blocker did not change endogenous thromboxane formation in the platelets of normal volunteers41,42 or alter the binding of prostaglandin D2 to rabbit platelets.43 Metoprolol might exert a protective effect on the cerebral circulation by altering the response to sudden bursts of catecholamine release during evolving myocardial infarction by dampening sudden increases in blood pressure, decreasing cardiac contractility, and decreasing the force of ventricular ejection.
The data of the TIMI II-B study indicate that intravenous metoprolol is safe to give to patients with evolving myocardial infarction undergoing reperfusion therapy with rt-PA. Immediate metoprolol therapy did not appear to improve global or regional left ventricular function measured at hospital discharge but was associated with decreased rates of myocardial ischemia and reinfarction over the same interval, and for this benefit 13-blockade is recommended in association with thrombolytic therapy. Total mortality was not altered by immediate 1-blocker therapy, although there were fewer deaths in the low-risk subgroup. The data suggest that intracranial hemorrhage occurs less frequently in patients receiving immediate ,3-blocker therapy than in patients in whom such therapy is deferred. However, this must be confirmed in a larger randomized population. 
